EGFRエクソン19挿入を伴う肺腺癌のコンパクトパネルによる同定とそのオシメルチニブへの反応：症例報告
Mika Horie1, Kazuhisa Nakashima1, Kojiro Hata1
1Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Abstract:
An 80-year-old man underwent a left lower lobectomy for lung adenocarcinoma. Next-generation sequencing in a clinical trial identified an epidermal growth factor receptor (EGFR) exon 19 insertion (exon19ins), which was not detected by the Oncomine™ Dx Target Test®, a companion diagnostic tool for EGFR mutations. However, the Lung Cancer Compact Panel® Dx (LCCP), another companion diagnostic tool, confirmed exon19ins. Osimertinib was administered, which led to a slight tumor response. This case suggests that LCCP may be useful in detecting rare EGFR mutations and that osimertinib may be effective against exon19ins.
